# Emerging Cancer Therapies Leveraging Gamma-Delta Effector T cells Symposium

## Event Schedule

**Mon, Nov 29, 2021**

### 11:00am

**Introduction**  
11:00am - 11:05am, Nov 29

#### Speaker

Dr. Andrea van Elsas  
Abata Therapeutics and Third Rock Ventures, Cambridge, MA

### 11:05am

**Butyrophilins and Vy9Vδ2-T cells: translating immune regulation to patients' treatments**  
11:05am - 11:30am, Nov 29

Prof. Olive’s presentation will address the roles of BTN3A and BTN2A1 in human primary tumors and will mainly focus on Vγ9Vδ2 T cell and cancer cells as well as their regulation, function and roles as biomarkers.

#### Speaker

Prof. Daniel Olive  
Imcheck and Aix-Marseille Université, Marseille, FR

### 11:30am

**Mastering T cell diversity for a successful clinical translation**  
11:30am - 11:55am, Nov 29

Overall, γδT cells display potent cytotoxicity, which usually does not depend on tumour-associated (neo)antigens, towards a large array of haematological and solid tumours, while preserving normal tissues. However, the precise mechanisms of tumour-specific γδT cells, as well as the mechanisms for self-recognition, remain poorly understood. Also a large diversity in terms of receptors and function is observed in this population. In this presentation, I therefore discuss functional diversity and diversity of subsets as well as receptors which I consider as major challenges but also opportunities for the clinical implementation of cancer immunotherapies based on γδT cells and their receptors.


#### Speaker

Prof. Jürgen Kuball  
University Medical Center, Utrecht, NL
11:55am

**Allogeneic T cell therapies**

(panel) 11:55am - 12:20pm, Nov 29

**Speaker**

Dr. Michael Koslowski  
GammaDelta Therapeutics, London, UK

12:20pm

**Bispecific antibodies to engage Vγ9Vδ2-T cells for cancer immunotherapy**

(pannel) 12:20pm - 12:45pm, Nov 29

Vγ9Vδ2-T cells constitute the largest γδ-T cell subset in human peripheral blood and are powerful anti-tumor immune effector cells. Vγ9Vδ2-T cell based cancer immunotherapy approaches explored thusfar demonstrated a good safety profile and incidental antitumor activity. In this presentation I will discuss the generation and characterization of bispecific antibodies (Gammabody™ platform) designed to trigger tumor-specific cytolytic activity of Vγ9Vδ2-T cells. The potential of this approach for the treatment of solid tumors will be illustrated using an EGFR-γδ bispecific T cell engager (bsTCE) and for hematological malignancies using the CD1d-γδ bsTCE LAVA-051, which is currently evaluated in a first-in-human clinical Phase 1/2a study in patients with CD1d-expressing CLL, MM, or AML refractory to prior therapy (NCT04887259).

**Speaker**

Prof. Hans van der Vliet  
LAVA Therapeutics and Amsterdam UMC, Utrecht, NL

12:45pm

**Break**

(pannel) 12:45pm - 1:00pm, Nov 29

1:00pm

**Discussion panel**

(pannel) 1:00pm - 1:45pm, Nov 29

**Speakers**

Prof. James Allison  
MD Anderson, Houston, TX

Prof. Padmanee Sharma  
MD Anderson, Houston TX
1:45pm

Wrap up by Dr. Andrea van Elsas
 1:45pm - 2:00pm, Nov 29

Dr. Andrea van Elsas Abata Therapeutics and Third Rock Ventures, Cambridge, MA

Powered By Whova